Tempus AI, Inc. revenue by segment TEM

Tempus AI, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Diagnostics at $955.4 million, 75% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line
FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Revenue
1,509
1,272
693
Diagnostics
—
955
+111.5%
share 75.1%
452
share 65.2%
Genomics Product
—
—
452
share 65.1%
Insights Product
—
258
+38.0%
share 20.3%
187
share 26.9%
Trials Product
—
38
-9.2%
share 3.0%
42
share 6.1%
AI Applications
—
20
+63.4%
share 1.6%
12
share 1.8%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Services-Computer Programming, Data Processing, Etc. (SIC 7370)
Listed as
TEM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Chicago, IL
SEC filer status
Large accelerated filer
SEC CIK
1717115
Former names
Tempus Labs, Inc. (until Dec 5, 2023)

Other Services-Computer Programming, Data Processing, Etc. companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.